EN106
Based on 1 publication(s) in Google Scholar
EN106 is a potent inhibitor of FEMIB. EN106 is a cysteine-reactive covalent ligand. EN106 disrupts recognition of the key reductive stress substrate of FEM1B, FNIP1. EN106 reduces oxidative stress and rescues high glucose-induced impaired angiogenesis in HUVECs.
For research use only. We do not sell to patients.
- Purity : 99.92%
- CAS No.: 757192-67-9
- Formula: C13H13ClN2O3
- Molecular Weight:280.71
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) EN106
More
Biological Activity
Description
In Vitro
EN106 (1 μM, 24 h) reduces the MDA content in HUVECs, inhibits the ROS generation and the activation of NF-κB signaling pathway, increases SOD activity, exhibiting antioxidant effects[2].
EN106 (1 μM, 24 h) increases the expression of cell cycle-related proteins (Cyclin D1, Cyclin D3) and VEGFA, promotes the cell proliferation, migration and angiogenesis in HUVEC, rescuing high glucose-impaired angiogenesis of HUVECs[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Mouse Streptozotocin (HY-13753)-induced type 2 diabetes models[2]
-
Dosage:
-
Administration:HA-PBA-FA/EN106 hydrogel, topical application, administration on days 0, 3, 5, 7, 10, and 14 after wound establishment.
-
Result:Accelerated the wound healing, promoted collagen deposition, upregulated the expression of FNIP1 and VEGFA proteins, increased the number of CD31(+) cells, and decreased the ROS level.
Chemical Information
-
CAS No. 757192-67-9
-
Appearance Solid
-
Molecular Weight 280.71
-
Formula C13H13ClN2O3
-
Color White to off-white
-
SMILES
O=C(N(CCC#N)C1=CC=C(OCCO2)C2=C1)CCl
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
bioRxiv
2026 May 8:2026.05.07.723605. PMID: 42146656
Solvent & Solubility
In Vitro:
DMSO : 250 mg/mL (890.60 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Human pluripotent stem cell endothelial-cell differentiation
Human pluripotent stem cell endothelial differentiation is based on stepwise developmental patterning: early activation of WNT/GSK3β inhibition promotes mesodermal or vascular progenitor entry, followed by endothelial specification using VEGF-related signaling, BMP4, FGF2, Notch modulation, or cAMP depending on the published protocol. Endothelial differentiation is read out by acquisition of CD31, CD34, VE-cadherin/CD144, KDR/VEGFR2, vWF, Tie2, NOS3, acetylated LDL uptake, tube/network formation, barrier function, and in vivo vessel-forming capacity where tested.
-
Vascular/Branching Fractal Analysis
Vascular/branching fractal analysis quantifies the geometric complexity of vessel trees or vascular networks from segmented 2D images, commonly by converting vessels into binary and/or skeletonized maps and estimating fractal dimension using box-counting or related approaches. Fractal dimension is interpreted as an image-derived readout of vascular branching complexity, space filling, or density, and has been applied to retinal photographs, fluorescein angiography, OCT angiography, capillary perfusion maps, and in vitro Matrigel angiogenesis networks. The assay readout is generated from vessel-positive pixels after image preprocessing, vessel segmentation, binarization, and optional skeletonization; reported outputs include fractal dimension, vessel density, branchpoint density, endpoint density, vessel length density, tortuosity, and generation-based branching metrics when VESGEN-style analysis is used. The biological interpretation is limited to quantitative vascular patterning and s
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Endothelial Tube Formation Assay
Endothelial tube formation assay evaluates the ability of endothelial cells to attach, migrate, align, and organize into capillary-like networks when cultured on gelled basement membrane extract or Matrigel; the readout is the morphology and quantity of tube-like networks, which reflects an in vitro endothelial morphogenesis step related to angiogenesis. Basement membrane extract/Matrigel provides laminin-rich extracellular matrix cues that support endothelial differentiation into capillary-like structures, but it can contain biologically active growth factors, so growth-factor-reduced matrix is preferred when testing defined angiogenic stimulators or inhibitors.
-
Endothelial Cell Migration/Angiogenic Sprouting Assay
Endothelial cell migration and angiogenic sprouting assays are in vitro (and partially ex vivo-adapted) functional models that quantify the ability of endothelial cells to undergo coordinated migration, extracellular matrix invasion, and multicellular organization into capillary-like sprouts in response to pro-angiogenic stimuli such as VEGF, bFGF, or conditioned microenvironments. These assays are used to model early angiogenic events including tip-cell formation, directional migration, and lumen-like sprout extension, which collectively reflect angiogenic activation and vascular morphogenesis processes observed in vivo.
Purity & Documentation
-
Data Sheet (277 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Henning NJ, et al. Discovery of a Covalent FEM1B Recruiter for Targeted Protein Degradation Applications. J Am Chem Soc. 2022;144(2):701-708. [Content Brief]
[2]. Zhang W, et al., Glucose-responsive, antioxidative HA-PBA-FA/EN106 hydrogel enhanced diabetic wound healing through modulation of FEM1b-FNIP1 axis and promoting angiogenesis. Bioact Mater. 2023 Jul 22;30:29-45. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.5624 mL | 17.8119 mL | 35.6238 mL | 89.0596 mL |
| 5 mM | 0.7125 mL | 3.5624 mL | 7.1248 mL | 17.8119 mL | |
| 10 mM | 0.3562 mL | 1.7812 mL | 3.5624 mL | 8.9060 mL | |
| 15 mM | 0.2375 mL | 1.1875 mL | 2.3749 mL | 5.9373 mL | |
| 20 mM | 0.1781 mL | 0.8906 mL | 1.7812 mL | 4.4530 mL | |
| 25 mM | 0.1425 mL | 0.7125 mL | 1.4250 mL | 3.5624 mL | |
| 30 mM | 0.1187 mL | 0.5937 mL | 1.1875 mL | 2.9687 mL | |
| 40 mM | 0.0891 mL | 0.4453 mL | 0.8906 mL | 2.2265 mL | |
| 50 mM | 0.0712 mL | 0.3562 mL | 0.7125 mL | 1.7812 mL | |
| 60 mM | 0.0594 mL | 0.2969 mL | 0.5937 mL | 1.4843 mL | |
| 80 mM | 0.0445 mL | 0.2226 mL | 0.4453 mL | 1.1132 mL | |
| 100 mM | 0.0356 mL | 0.1781 mL | 0.3562 mL | 0.8906 mL |